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INTRODUCTION

Age-related macular degeneration (AMD) is the leading cause of blindness among elderly
Electronic supplementary material The online version of this article (doi:10.1007/s40123-015-0031-5) contains supplementary material, which is available to authorized users. patients in developed countries [1, 2] . While the neovascular form of AMD (nAMD) characterized by choroidal neovascularization (CNV) comprises approximately 10% of the disease, it is responsible for over 90% of cases of severe visual loss [3] [4] [5] . Over the last few years, introduction of anti-vascular endothelial growth factor (anti-VEGF) therapy, such as ranibizumab, has revolutionized the management of nAMD. The latter has been approved for use on the basis of phase III clinical trials with monthly follow-up and treatment over 24 months [6, 7] . Further research trialed anti-VEGF regimens of varying dosage and frequency of therapy administration, in an attempt to maximize visual acuity (VA) outcomes while minimizing treatment burden [8] [9] [10] [11] [12] [13] [14] . In studies reporting sustained improvements in vision, patients had very frequent follow-ups with monthly ophthalmic examinations. However in clinical practice, patients with nAMD often have significant coexisting medical conditions, which may impact on their ability to attend their regular AMD clinic appointments [6, 10] . It is also important to note that clinical trials often exclude patients who may not comply with mandated study visits and may only include patients who are able to attend monthly follow-up visits [12] . This may mean that in practice, the intensive follow-up and treatment paradigms used in clinical trials may be difficult to implement. If this is indeed a significant problem, then it has the potential to impact on the outcomes of therapy in clinical practice, as less intensive follow-up can result in poorer outcomes of treatment [15, 16] .
The aim of this study was to report the proportion of patients with missed hospital appointments (MHAs) for nAMD assessment in a consecutive cohort of patients treated with ranibizumab and to report the duration of such 
RESULTS
During the interval chosen for the study, 78 eyes of 78 patients met the inclusion criteria for data analysis. The mean age was 78 years (range 52-93 years) and the mean follow-up was 27 months (range 24-38 months). There were 43 women (55%) and all 78 patients were Caucasian. Mean VA was 52 ± 16 letters at baseline, 56 ± 17 letters at year 1 and 58 ± 16 letters at year 2. At the end of the second year, 90% of the patients had lost \15 letters, 26% had gained C15 letters and 10% had lost C15 letters. Mean CRT was 311 ± 87 lm at baseline, 273 ± 72 lm at year 1 and 250 ± 68 lm at year 2. Mean number of injections was 6.7 (range 3-12) in the first year and 4.9 (range 0-12) in the second year. Mean number of hospital visits was 9.4 (range 5-12) in the first year and 8.9
(range 3-12) in the second year. Nineteen patients had at least one MHA (24%). Two patients had three MHAs, 3 patients had two MHAs and 14 patients had one MHA. There were 26 MHA episodes in total with a median duration of 79 days (range 35-159). None of these MHAs occurred during the first 3 months after treatment initiation. Table 1 summarizes baseline demographics, baseline lesion size and subtypes for the two groups. Table 2 displays  the treatment-related metrics and Table 3 summarizes the outcomes of ranibizumab therapy. There was no statistically significant difference between the two groups regarding baseline age, baseline VA, baseline CRT and baseline lesion size. In addition, the two groups were similar in terms of baseline lesion type (Table 1) Hospital visits during the 1st year (mean ± SD)
Hospital visits during the 2nd year (mean ± SD)
MHAs missed hospital appointments MHAs missed hospital appointments, VA visual acuity, ETDRS Early Treatment Diabetic Retinopathy Study, CRT central retinal thickness ranibizumab therapy. In this study we found that although MHAs were not uncommon in patients who had been undergoing ranibizumab therapy over a minimum of 24 months occurring in 24% of patients, there was no significant impact on the outcomes of treatment when compared with a group of consecutively treated patients without MHAs over the same period. We found that median duration of MHAs was less than 3 months (78.5 days). This may explain why no differences were seen in the outcomes of treatment in the groups with or without MHAs. Furthermore, over 2 years, there were a similar number of hospital visits and ranibizumab injections in both groups suggesting that when an MHA occurred, a new clinic appointment was made relatively rapidly, reducing the review-free interval and potentially preventing vision loss. This work suggests that good treatment outcomes with ranibizumab can be achieved with nine hospital visits in the first year and nine hospital visits in the second year.
In the first year this would mean a hospital visit on average every 7 weeks after the initial loading phase of treatment (when an injection is given every 4 weeks for 3 injections) and every 5.8 weeks in the second year of treatment.
There are many weaknesses in this work including its retrospective nature and nonstandardized approach to treatment and limited sample size; however there are also several strengths including the report of ''reallife'' outcomes from patients treated at a large tertiary referral center.
CONCLUSION
These data suggest that missed hospital visits may be a relatively common occurrence in AMD treatment clinics, but good outcomes of treatment can be achieved over 2 years if patients are reviewed on average six times in the first year after an initial loading phase of three injections (one injection a month for 3 months) and nine times in the second year of treatment.
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